Aspire Biopharma Holdings Inc (ASBP)

07:25 AM

Aspire Biopharma Provides Q3 2025 Business Update - The Florida Times-Union

07:25 AM

06:50 AM

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech

06:50 AM

Dec 14, 2025

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Peoria Journal Star

Dec 14, 2025

Dec 13, 2025

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements - 富途牛牛

Dec 13, 2025

Dec 12, 2025

Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com - Investing.com Nigeria

Dec 12, 2025

Dec 12, 2025

Aspire Biopharma gets Nasdaq extension to meet listing requirements - Investing.com

Dec 12, 2025

Dec 12, 2025

POWP ACQUPAR : Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - marketscreener.com

Dec 12, 2025

Dec 12, 2025

Aspire Biopharma (Nasdaq: ASBP) gains extension, moves to Nasdaq Capital Market - Stock Titan

Dec 12, 2025

Dec 08, 2025

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Pensacola News Journal

Dec 08, 2025

Dec 06, 2025

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Victorville Daily Press

Dec 06, 2025

Dec 05, 2025

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Alliance Review

Dec 05, 2025

Dec 04, 2025

Aspire Biopharma advances sublingual drug delivery technology By Investing.com - Investing.com Nigeria

Dec 04, 2025

Dec 04, 2025

Aspire Biopharma advances sublingual drug delivery technology - Investing.com

Dec 04, 2025

Dec 04, 2025

Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data - Stock Titan

Dec 04, 2025

Dec 02, 2025

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Montgomery Advertiser

Dec 02, 2025

Dec 02, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Dec 02, 2025

Dec 02, 2025

Aspire Biopharma (NASDAQ: ASBP) Requests FDA Pre-IND Meeting on Sublingual AMI Aspirin - Stock Titan

Dec 02, 2025